Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner
Ryvu Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Stock Price

ZŁ48.3

2024-10-29

Market Capitalization

ZŁ1.2 B

2024-10-29

Revenue

ZŁ62.3 M

FY, 2025

CreditSafe Score

?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

PLNFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022FY, 2023FY, 2024FY, 2025
Revenue77.2M42.6M15.7M11.8M38.9M46.9M78.0M62.3M
Cost of goods sold57.7M63.1M32.9M47.4M58.9M84.8M133.6M113.3M
Gross profit52.4M11.4M4.4M(9.9M)10.4M(16.8M)(31.5M)(25.6M)
Gross profit margin, %67.8%26.8%28.1%-83.4%26.7%-35.8%-40.5%-41.1%
Operating expense total57.8M45.6M27.7M32.4M46.0M61.3M75.8M59.4M
Depreciation and amortization8.2M10.9M12.4M12.6M12.9M11.0M10.5M9.4M
EBITDA(5.4M)(33.3M)(18.0M)(42.3M)(35.6M)(78.1M)(107.3M)(85.0M)
EBITDA margin, %-7.0%-78.2%-114.7%-357.5%-91.4%-166.6%-137.7%-136.5%
EBIT(13.6M)276.8M(30.3M)(54.9M)(48.5M)(89.1M)(117.8M)(94.4M)
EBIT margin, %-17.6%650.3%-193.7%-463.6%-124.5%-190.1%-151.1%-151.7%
Interest income1.4M907.0K219.0K61.0K1.1M13.8M9.1M5.1M
Interest expense315.0K397.0K386.0K442.0K1.1M97.0K3.8M8.8M
Pre tax profit9.0M285.8M(30.6M)(77.4M)(79.2M)(92.1M)(111.1M)(101.1M)
Income tax expense8.1M161.0K1.1M116.0K4.6M297.0K88.0K
Net Income893.0K285.6M(31.7M)(77.5M)(83.8M)(92.1M)(111.4M)(101.2M)

Footer menu